Kygevvi
What Kygevvi is used for
Kygevvi is indicated for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Kygevvi
- Active substance
- doxecitine;doxribtimine
- Disease area
- Mitochondrial Diseases
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AX29
- Marketing authorisation holder
- UCB Pharma
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Kygevvi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kygevvi used for?
Kygevvi is indicated for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
What is the active substance in Kygevvi?
Kygevvi contains doxecitine;doxribtimine.
Who makes Kygevvi?
The EU marketing authorisation holder is UCB Pharma.
Is Kygevvi an orphan medicine?
Yes. Kygevvi is designated an orphan medicine in the EU, for a rare disease (Mitochondrial Diseases).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU